ArticlePatient related outcome measures2026
Digital patient-reported outcomes to evaluate treatment response to filgotinib in patients with ulcerative colitis.
Article in Patient related outcome measures, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Patient-reported outcomes (PROs) are valuable tools for improving long-term patient outcomes and providing patient-centered care. PROs can be used to investigate real-world treatment effectiveness in patients with a chronic inflammatory disease. Methods: This was a real-world cohort study with digital patient-reported data collection by patients with ulcerative colitis (UC) using TrueColours-IBD, a web-based platform for prospective monitoring of symptoms, quality of life, and outcomes in Oxford. Effectiveness of filgotinib was compared between advanced therapy-naïve (ATN, i.e. filgotinib 1st line, Results: There were no significant differences between the ATN and ATE groups regarding clinical remission, response, and corticosteroid-free remission at any time point, with Conclusion: This study shows that PROs can serve as an important tool in evaluating real-world treatment outcomes in patients with UC using filgotinib. The results demonstrate good subjective clinical effectiveness, regardless of prior advanced therapy exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.